Madrigal Pharmaceuticals, Inc. MDGL Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s business segments — stock-based comp?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported business segments — stock-based comp of $26.06M in Q1 2026.
- What does business segments — stock-based comp mean?
- The non-cash cost of paying employees and executives with company stock.
- How do you interpret business segments — stock-based comp?
- High levels relative to revenue may indicate aggressive talent acquisition or dilution concerns for shareholders.
- How does business segments — stock-based comp compare across companies?
- Widely reported by public companies as a non-cash operating expense.